<DOC>
	<DOCNO>NCT01728493</DOCNO>
	<brief_summary>Primary aldosteronism ( PA ) frequent form secondary hypertension . It cause autonomous secretion aldosterone , encompass group disorder 99 % predominated unilateral aldosterone-producing adenoma ( APA ) bilateral adrenal hyperplasia ( BAH ) . Diagnosis PA relevant two reason : 1. independent level blood pressure , hypertension due autonomous aldosterone secretion cause cardiovascular damage essential hypertension ; 2 . PA require specific treatment : adrenalectomy case APA mineralocorticoid receptor antagonist ( MRA ) case BAH . Although previously presume rare condition ( prevalence &lt; 1 % ) , PA estimate affect 6 20 % hypertensive population . Given high prevalence PA , well amount cardiovascular damage available specific treatment , question raise whether screen PA introduce Dutch general practice . To answer important question , several issue regard PA need elucidate : 1. International study report prevalence PA general practice 6-13 % . Prevalence Dutch population still unknown ; 2 . Because underdiagnosis PA long delay diagnosis PA recognition hypertension ( mean eight year ) , data characteristic early diagnose PA lack . Proof early cardiovascular damage would strengthen case screen PA need study ; 3 . Consequently , diagnostic delay lead lack data optimal treatment early PA . In current guideline ( NHG-guideline 'Cardiovascular risk management ' ) regimen antihypertensive drug advise , hypertension refractory &gt; 6 month patient refer . It unknown hypertension resistant therapy initial phase PA . If , would also argue early biochemical screening PA , even blood pressure control , detrimental effect aldosterone go unopposed . It therefore require study response antihypertensive drug ( MRA ) patient .</brief_summary>
	<brief_title>Primary Aldosteronism General Practice : Organ Damage , Epidemiology Treatment</brief_title>
	<detailed_description>Rationale : Primary aldosteronism ( PA ) frequent form secondary hypertension . It cause autonomous secretion aldosterone , encompass group disorder 99 % predominated unilateral aldosterone-producing adenoma ( APA ) bilateral adrenal hyperplasia ( BAH ) . Diagnosis PA relevant two reason : 1 ) independent level blood pressure , hypertension due autonomous aldosterone secretion cause cardiovascular damage essential hypertension ; 2 ) PA require specific treatment : adrenalectomy case APA mineralocorticoid receptor antagonist ( MRA ) case BAH . Although previously presume rare condition ( prevalence &lt; 1 % ) , PA estimate affect 6 20 % hypertensive population . Given high prevalence PA , well amount cardiovascular damage available specific treatment , question raise whether screen PA introduce Dutch general practice . To answer important question , several issue regard PA need elucidate : 1. International study report prevalence PA general practice 6-13 % . Prevalence Dutch population still unknown ; 2 . Up , laboratory test screening PA , aldosterone/renin ratio ( ARR ) , primarily use secondary care . The relation ARR outcomes primary care unknown ; 3 . Because underdiagnosis PA long delay diagnosis PA recognition hypertension ( mean eight year ) , data characteristic early diagnose PA lack . Indications early cardiovascular damage would strengthen case screen PA need study .</detailed_description>
	<mesh_term>Hyperaldosteronism</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<criteria>Part 1 : 1 . Newly diagnose hypertensive patient ( accord NHGguideline 'Cardiovascular risk management ' ) ; 2 . 18 year old ; 3 . No use antihypertensive medication . Part 2 : 1 . Patients increase aldosterone/renin ratio ; 2 . Positive sodium load test ; 3 . Written informed consent . Part 2 + 3 : 1 . Patients normal aldosterone/renin ratio ; 2 . Normal ARR ; 3 . Written informed consent . Part 3 : 1 . Patients increase aldosterone/renin ratio ; 2 . Positive sodium load test ; 3 . Normokalemic ; 4 . Written informed consent . 1 . Use antihypertensive medication ; 2 . Heart failure class II , III IV ( accord New York Heart Association ) ; 3 . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Prevalence</keyword>
	<keyword>Primary aldosteronism</keyword>
	<keyword>Organ damage</keyword>
	<keyword>Mineralocorticoid receptor antagonist</keyword>
</DOC>